| Expression pattern: |
UP |
| Associated gene: |
MTA1 |
| Associated microRNA: |
miR-661 |
| Biological function: |
Promotes TNBC cell proliferation, migration, tumour growth and metastasis, and inhibits apoptosis. |
| Molecular mechanism: |
circ-UBAP2 acts as a cytoplasmic ceRNA that sponges miR-661 to increase MTA1 expression, thereby promoting TNBC progression. |
| Biological pathway or process: |
proliferation (promotes); migration (promotes); metastasis (promotes); apoptosis (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RT-qPCR; Clinical Sample Validation; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; Bioinformatics Analysis; circRIP; Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Transwell Assay; Annexin V/PI Flow Cytometry; Western Blot; IHC (Immunohistochemistry); In Vivo Animal Model; H&E Staining; Survival Analysis; Cohort Study |
| Clinical significance: |
High circ-UBAP2 expression was associated with larger tumour size, advanced TNM stage, lymph node metastasis and unfavourable prognosis; circ-UBAP2 may serve as a prognostic biomarker and therapeutic target for TNBC. |
| Description: |
circ-UBAP2 is upregulated in TNBC tissues and cell lines and high expression predicts poor overall survival. Functionally, circ-UBAP2 promotes TNBC proliferation, migration, tumour growth and metastasis while suppressing apoptosis. Mechanistically, it mainly localizes in the cytoplasm and acts through the miR-661/MTA1 ceRNA axis. |
| Confidence score: |
0.8192 |